SGLT‐2 Inhibitors Use in Hospitalized Patients in France: A Cross‐Sectional Study
Fundamental & Clinical Pharmacology · 2026
DOI: 10.1111/fcp.70076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2026. Verfasst von Maxime Demourgues und 5 weiteren Autor:innen. Beteiligte Einrichtung: Inserm U1219, Bordeaux Population Health Research Center, Team AHeaD, Department of Medical Pharmacology, CHU de Bordeaux, University of Bordeaux, Bo…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Heart Failure. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Agence Nationale de Sécurité du Médicament et des Produits de Santé.
Abstract (Originalsprache)
Background
Sodium glucose co‐transporter type 2 inhibitors (SGLT2i) were initially developed as glucose‐lowering drugs for diabetic patients. A few years after their market authorization in Europe, their indications were expanded to include first, heart failure (HF) and, subsequently, chronic kidney disease (CKD). These expansions led to a rapid increase in the use of this drug class and a diversification of the treated patient profile in the “real‐life.” Objectives Describe in‐hospital SGLT2i user profiles and evaluate compliance with guidelines.
Methods
A descriptive cross‐sectional study was conducted using the Bordeaux University Hospital's clinical data warehouse. It included a random sample of 250 hospital stays of different patients with at least one administration of SGLT2i between February 1, 2022, and January 31, 2023. SGLT2i user profiles were described in terms of indications. Drug co‐prescriptions were also described to evaluate compliance with guidelines.
Results
The majority of patients were aged 60–79 (59.6%), and were men (75.2%). HF was found in 87.2% of the patients treated with SGLT2i, followed by T2DM (45.2%) and CKD (21.2%). The most frequent indication profiles were HF without type II diabetes or CKD (42.0%) followed by HF and diabetes without CKD (26.0%). No patient had CKD as the sole indication. Prescriptions were considered compliant with guidelines for 76.4% of patients. Suboptimal prescriptions were mainly due to absence of another recommended drug without justification.
Conclusion
SGLT2i are now primarily used to treat HF. Their therapeutic potential in CKD appears to be still underestimated. Overall, compliance with guidelines appears satisfactory.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inserm U1219, Bordeaux Population Health Research Center, Team AHeaD, Department of Medical Pharmacology, CHU de Bordeaux, University of Bordeaux, Bordeaux, France.
- CHU de Bordeaux, Pôle de Santé Publique, Service d'information Médicale, Informatique et Archivistique Médicales (IAM), Bordeaux, France.
ORCID-Profile: Maxime Demourgues
Förderung
- Agence Nationale de Sécurité du Médicament et des Produits de Santé
Zitieren
APA
Demourgues, M., Bezin, J., Griffier, R., Pariente, A., Noize, P., & de Germay, S. (2026). SGLT‐2 Inhibitors Use in Hospitalized Patients in France: A Cross‐Sectional Study. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.70076
Vancouver
Demourgues M, Bezin J, Griffier R, Pariente A, Noize P, de Germay S. SGLT‐2 Inhibitors Use in Hospitalized Patients in France: A Cross‐Sectional Study. Fundamental & Clinical Pharmacology. 2026. doi:10.1111/fcp.70076
BibTeX
@article{Demourgues2026,
author = {Demourgues, Maxime and Bezin, Julien and Griffier, Romain and Pariente, Antoine and Noize, Pernelle and de Germay, Sibylle},
title = {SGLT‐2 Inhibitors Use in Hospitalized Patients in France: A Cross‐Sectional Study},
journal = {Fundamental & Clinical Pharmacology},
year = {2026},
doi = {10.1111/fcp.70076}
}
EUVIMED